4E1RCat
SIGMA/SML0197 - ≥97% (HPLC)
Synonym: 4-
Empirical Formula (Hill Notation): C28H18N2O6
Molecular Weight: 478.45
MDL Number: MFCD01931282
Linear Formula: C28H18N2O6
Product Type: Chemical
| assay | ≥97% (HPLC) |
| color | faint brown to dark brown-red |
| form | powder |
| InChI | 1S/C28H18N2O6/c31-27-21(1 |
| InChI key | BBQRBOIMSKMFFO-LTGZKZEYSA |
| originator | Merck & Co., Inc., Kenilworth, NJ, U.S. |
| Quality Level | 100  |
| SMILES string | OC(=O)c1ccc(cc1)N2C(=O)C |
| solubility | DMSO: ≥5 mg/mL |
| storage temp. | 2-8°C |
| Application: | 4E1RCat was used to inhibit new protein synthesis in transformed primary chicken embryo fibroblasts. |
| Biochem/physiol Actions: | 4E1RCat ilnhibits the eIF4F translation initiation complex by binding to IF4E b and inhibiting the interaction between IF4E:eIF4G (IC50 = 3.2 μM). In in vitro translation experiments using MDA-MB-231 cells, 4E1RCat dose dependently inhibited cap-dependent translation, led to a decrease in polysome and 80S ribosomal subunits and reduced levels of the eIF4F-dependant proteins Mcl-1 and c-Myc. |
| Features and Benefits: | This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm . |
| Features and Benefits: | This compound is featured on the MAPKAPs page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here . |
| Features and Benefits: | This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S. . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 5, 25 mg in glass bottle |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥97% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |